and I agree. The point of my exchange with you was based on the following statement you made..
"I think the blog entry was pretty fair and balanced, but again failed to mention the single-blastomere technology (even though it's not being used for this trial)."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.